Dr. Mehta on the Role of Biomarkers in Gastric Cancer

Video

In Partnership With:

Rutika J. Mehta, MD, MPH, discusses the role of biomarkers in gastric cancer.

Rutika J. Mehta, MD, MPH, a medical oncologist specializing in gastrointestinal cancer at Moffitt Cancer Center, discusses the role of biomarkers in gastric cancer.

Biomarkers such as microsatellite instability, mismatch repair ​deficiency, HER2 status, PD-L1 ​status, and tumor mutational burden are of interest in the gastric cancer space, says Mehta.

​Moreover, according to Mehta, all patients ​with metastatic disease should be ​molecularly profiled. 

​Additionally, if tissue is available, ordering next​-generation sequencing may be beneficial ​in terms of treatment selection and identifying available clinical trials, Mehta concludes. 

Related Videos
Robert Dreicer, MD, director, Solid Tumor Oncology, Division of Hematology/Oncology, professor of Medicine and Urology, deputy director, University of Virginia Cancer Center
Akriti Jain, MD
Samer A. Srour, MB ChB, MS
Rebecca Kristeleit, BSc, MBChB, MRCP, PhD
Julia Foldi, MD, PhD
Carmen Guerra, MD, MSCE, FACP
Kara N. Maxwell, MD, PhD
Abdulrahman Sinno, MD
Margaret E. Gatti-Mays, MD, MPH, FACP, of The Ohio State University Comprehensive Cancer Center
Erin K. Crane, MD, MPH